Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Should Patients at High Risk of Peritoneal Dissemination from Gastric and Colon cancers Undergo HIPEC as an Adjuvant Therapy?

Should Patients at High Risk of Peritoneal Dissemination from Gastric and Colon cancers Undergo HIPEC as an Adjuvant Therapy?

FromSurgOnc Today®


Should Patients at High Risk of Peritoneal Dissemination from Gastric and Colon cancers Undergo HIPEC as an Adjuvant Therapy?

FromSurgOnc Today®

ratings:
Length:
20 minutes
Released:
Apr 20, 2021
Format:
Podcast episode

Description

In this episode, Edward Levine, MD Chair of the SSO Peritoneal Surface Malignancy DSWG, is joined by Brian Badgwell, MD of MD Anderson Cancer Center and Pieter Tanis, MD, PhD of the University of Amsterdam.  They discuss whether patients at high risk of peritoneal dissemination from gastric and colon cancers should undergo HIPEC as an adjuvant therapy. 
Released:
Apr 20, 2021
Format:
Podcast episode

Titles in the series (99)

SurgOnc Today® is an educational podcast for cancer surgeons from the Society of Surgical Oncology. Each episode features conversations with individuals who are experts within their respective fields and are members of SSO.